Could a single rituximab infusion tame Immunotherapy's harsh side effects?
Disease control
Not yet recruiting
This trial investigates whether a single ultra-low dose of rituximab can safely manage immune-related side effects caused by checkpoint inhibitor therapy in people with malignant melanoma. Participants receive one 100 mg infusion of rituximab along with a steroid tapering plan an…
Phase: PHASE1 • Sponsor: Inge Marie Svane • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC